ClinicalTrials.gg
CompletedNCT02143648Updated May 21, 2025Results posted

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

A Phase 2/3 interventional study of nalbuphine HCl ER tablets 60 mg BID and nalbuphine HCl ER tablets 120mg BID in Uremic Pruritus and Pruritus, sponsored by Trevi Therapeutics. Completed at 47 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Trevi Therapeutics · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
373
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.

Enrollment
17th of 153
373 · median 70
Started
2014
with 8 others
Phase 2/3
5 of 163
none open now
Registered
43rd of 163
by date

Among the 163 studies in Pruritus with a site in United States, this one is the 17th largest by enrollment of the 153 interventional ones that give a count, is one of 9 that started in 2014, is one of 5 in phase 2/3, and was the 43rd registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies in Pruritus with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of the study to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in hemodialysis patients with moderate to severe uremic pruritus and to evaluate the safety and tolerability in the study population.

03

Conditions studied

  • Uremic Pruritus
  • Pruritus

Browse trials for

Keywords

  • uremic
  • pruritus
  • itch
  • chronic itch
  • nalbuphine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has been receiving in-center hemodialysis for ≥ 3 months and are currently on a schedule of 3 times a week.
  • Subject self-categorized themselves on the Patient Assessed Disease Severity Scale during Screening
  • Subject meets standard of care hemodialysis efficiency guidelines during the three months prior to completing Screening
  • Have demonstrated pruritus intensity on the Itch NRS during screening
  • Male or female who are at least 18 years old at the time of Screening

Exclusion criteria

Exclusion Criteria:

  • Subject had a significant alteration in dialysis regimen during the Screening Period
  • Subject receiving or anticipated to be receiving nocturnal dialysis or home hemodialysis treatment during the study.
  • Subject has pruritus that is believed to be caused by a condition unrelated to end-stage renal disease
  • Has had a history of substance abuse within 6 months prior to completing Screening
  • Subject has a known drug allergy to opioids
  • Subject is a pregnant or lactating female.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
373 participants (actual)

Study arms

  • Experimental
    nalbuphine HCl ER 60mg

    nalbuphine HCl ER tablets 60 mg BID

    Drug: nalbuphine HCl ER tablets 60 mg BID

  • Experimental
    nalbuphine HCl ER 120mg

    nalbuphine HCl ER tablets 120 mg BID

    Drug: nalbuphine HCl ER tablets 120mg BID

  • Placebo comparator
    Sugar pill

    Placebo tablets BID

    Drug: Placebo tablets BID

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale

    The evaluation period was defined as the average itch score over weeks 7 and 8 following initiation of treatment. A negative change form baseline (Evaluation Period - Baseline) signified inmprovement.

    Time frame: 8 weeks

07

Results

Posted Sep 7, 2020

Participant flow

Participant flow — Overall Study
MilestoneNalbuphine HCl ER 60mgNalbuphine HCl ER 120mgSugar Pill
Started128120125
Completed7478101
Not completed544224

Outcome measures

PrimaryChange From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale

The evaluation period was defined as the average itch score over weeks 7 and 8 following initiation of treatment. A negative change form baseline (Evaluation Period - Baseline) signified inmprovement.

Time frame:
8 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale
units on a scaleNalbuphine HCl ER 60mgNalbuphine HCl ER 120mgSugar Pill
Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale-3.10 ± 2.35-3.49 ± 2.37-2.80 ± 2.22

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nalbuphine HCl ER 60mg0/126 (0%)16/126 (12.7%)0/126 (0%)
Nalbuphine HCl ER 120mg0/120 (0%)8/120 (6.7%)0/120 (0%)
Sugar Pill0/123 (0%)19/123 (15.4%)0/123 (0%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventNalbuphine HCl ER 60mgNalbuphine HCl ER 120mgSugar Pill
Cardiac failure congestiveCardiac disorders4/1261/1200/123
Gastrointestinal haemorrhageGastrointestinal disorders4/1260/1200/123
HyperkalemiaMetabolism and nutrition disorders2/1261/1203/123
Fluid overloadMetabolism and nutrition disorders1/1261/1202/123
SyncopeNervous system disorders0/1260/1202/123
AnaemiaBlood and lymphatic system disorders2/1260/1202/123
PneumoniaInfections and infestations0/1260/1202/123
SepsisInfections and infestations0/1260/1202/123
DiarrhoeaGastrointestinal disorders0/1261/1200/123
Transient ischemic attackNervous system disorders1/1261/1200/123

Baseline characteristics

Of the initial 373 participants randomized, 4 were never treated and, therefore, are not included in baseline demographic or frequency tables of treatment emrgent adverse events (TEAEs). Thus, the number of treated particpants was 369.

Age, Continuous
Age, Continuous(years)Nalbuphine HCl ER 60mgNalbuphine HCl ER 120mgSugar PillTotal
Mean55.0 ± 12.155.2 ± 12.256.5 ± 13.055.6 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Nalbuphine HCl ER 60mgNalbuphine HCl ER 120mgSugar PillTotal
Female585149158
Male686974211
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nalbuphine HCl ER 60mgNalbuphine HCl ER 120mgSugar PillTotal
Hispanic or Latino23201861
Not Hispanic or Latino103100105308
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nalbuphine HCl ER 60mgNalbuphine HCl ER 120mgSugar PillTotal
American Indian or Alaska Native1236
Asian1012
Native Hawaiian or Other Pacific Islander1001
Black or African American665560181
White576259178
More than one race0101
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Nalbuphine HCl ER 60mgNalbuphine HCl ER 120mgSugar PillTotal
Europe23232369
United States10397100300
08

Study locations

47 sites
  • Nephrology Associates PC
    Birmingham, Alabama 35211, United States
  • University South Alabama Medical Center
    Mobile, Alabama 63317, United States
  • Arizona Kidney Disease and Hypertension Center
    Phoenix, Arizona 85012, United States
  • U.S. Renal Care Inc
    Pine Bluff, Arkansas 76103, United States
  • North America Research Institute
    Azusa, California 91702, United States
  • Pegasus Dialysis, LLC
    Bakersfield, California 93308, United States
  • Central Nephrology Medical Group
    Bakersfield, California 93309, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Mark Lee MD, Inc
    Whittier, California 90606, United States
  • Nephrology and Hypertension Associates PC
    Middlebury, Connecticut 06762, United States
  • DaVita Inc Clinical Research Unit
    Stamford, Connecticut 06902, United States
  • Nephrology Center DBA Paragon Health
    Miami, Florida 33162, United States
  • Pines Clinical Research Inc
    Pembroke Pines, Florida 33028, United States
  • Genesis Clinical Research
    Tampa, Florida 33614, United States
  • DaVita Central Orlando Dialysis
    Winter Park, Florida 32789, United States
  • Southwest Georgia Nephrology Clinic PC
    Albany, Georgia 31701, United States
  • Renal Physicians of Georgia
    Macon, Georgia 31217, United States
  • Pacific Renal Research Institute
    Meridian, Idaho 83642, United States
  • Fresenius Medical Care of Evergreen Park
    Evergreen Park, Illinois 60805, United States
  • Western New England Renal and Transplant Association
    Springfield, Massachusetts 01107, United States
  • McComb Limited Care Facility
    McComb, Mississippi 39648, United States
  • Kidney Associates of Kansas City PC
    Kansas City, Missouri 64131, United States
  • Nephrology-Hypertension Associates of Central New Jersey PA
    North Brunswick, New Jersey 80902, United States
  • Renal Medicine Associates
    Albuquerque, New Mexico 87109, United States
  • Newtown Dialysis Center, Inc
    College Point, New York 11356, United States
  • DaVita Northtown's Dialysis Center
    Tonawanda, New York 14150, United States
  • Durham Nephrology Associates
    Durham, North Carolina 27704, United States
  • Wake Nephrology Associates PA
    Raleigh, North Carolina 27609, United States
  • Brookview Hills Research Associates LLC
    Winston-Salem, North Carolina 27103, United States
  • University Of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Nephrology Research Consortium
    Bethlehem, Pennsylvania 18017, United States
  • Delaware Valley Nephrology
    Philadelphia, Pennsylvania 19118, United States
  • Dialysis Clinic Inc.
    Philadelphia, Pennsylvania 19129, United States
  • South Carolina Nephrology and Hypertension
    Hampton, South Carolina 29924, United States
  • South Carolina Nephrology and Hypertension
    Orangeburg, South Carolina 29118, United States
  • Carolina Diabetes and Kidney Center
    Sumter, South Carolina 29150, United States
  • Southwest Renal Research Institute
    Chattanooga, Tennessee 37408, United States
  • U.S. Renal Care Inc
    Fort Worth, Texas 76105, United States
  • U.S Renal Care Inc.
    Fort Worth, Texas 76164, United States
  • U.S. Renal Care Inc.
    Mansfield, Texas 76063, United States
  • Fresenius Medical Care Shorewood
    Shorewood, Wisconsin 53211, United States
  • Norbert Barlicki University Hospital No1. of the Medical University of Lodz
    Lodz, 90-153, Poland
  • International Healthcare Systems S.A IHS Craiova Dialysis Center
    Craiova, Dolj 200347, Romania
  • International Healthcare Systems S.A IHS Fundeni Dialysis Center
    Bucharest, 022325, Romania
  • S.C Gral Medical S.R.L
    Bucharest, 031422, Romania
  • S.C Diaverum Romania S.R.I, Industriilor Diaverum Dialysis Center
    Bucharest, 032895, Romania
  • SC Diaverum Romania SRL, Splai Dialysis Center
    Bucharest, 060021, Romania
09

References and documents

Publications

  • Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020 Dec 7;12(12):CD011393. doi: 10.1002/14651858.CD011393.pub2. PubMed 33283264 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2020, 5 years 2 months after primary completion. A results delay was requested in May 2017.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2014
First posted
May 21, 2014
Start
Jun 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results delay requested
May 25, 2017
Results first posted
Sep 7, 2020
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02143648
Lead sponsor
Trevi Therapeutics
Responsible party
Sponsor
First posted
May 21, 2014
Start date
Jun 2014
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Sep 7, 2020
Last update
May 21, 2025

Study contacts

Chief Development Officer
study director · Trevi Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion